Performance evaluation of the Biocartis Idylla EGFR Mutation Test using pre-extracted DNA from a cohort of highly characterised mutation positive samples
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Pathology"
DOI: 10.1136/jclinpath-2020-207338
Abstract: Aims Targeted therapies for non-small cell lung carcinoma (NSCLC) rely on the detection of specific genomic lesions, such as mutations within the epidermal growth factor receptor (EGFR) gene. The Biocartis Idylla platform and single-use EGFR… read more here.
Keywords: extracted dna; input; idylla egfr; test ... See more keywords
Idylla EGFR assay on extracted DNA: advantages, limits and place in molecular screening according to the latest guidelines for non-small-cell lung cancer (NSCLC) patients
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pathology"
DOI: 10.1136/jcp-2022-208325
Abstract: Aims Idylla epidermal growth factor receptor (EGFR) is a fast and fully automated mutation assay that is easy to implement. However, under the Biocartis-recommended technical conditions, tissue sections are directly introduced into the cartridge, at… read more here.
Keywords: dna; non small; small cell; idylla egfr ... See more keywords
Performance of Ultra-Rapid Idylla™ EGFR Mutation Test in Non-Small-Cell Lung Cancer and Its Potential at Clinical Molecular Screening
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15092648
Abstract: Simple Summary Genetic information is essential before starting the treatment of advanced-stage non-small-cell lung cancer (NSCLC) and in the adjuvant setting (EGFR mutation status only) after pulmonary resection of early-stage NSCLC. Several genetic tests for… read more here.
Keywords: mutation test; mutation; idylla egfr; egfr mutation ... See more keywords
Improving Time-to-Treatment for Advanced Non-Small Cell Lung Cancer Patients through Faster Single Gene EGFR Testing Using the Idylla™ EGFR Testing Platform
Sign Up to like & getrecommendations! Published in 2022 at "Current Oncology"
DOI: 10.3390/curroncol29100624
Abstract: Introduction: Patients with advanced-stage non-small cell lung cancer (NSCLC) may benefit from a short time-to-treatment (TTT). Predictive biomarker testing is performed prior to treatment, as recommended by various international expert consensus bodies. Genetic testing is… read more here.
Keywords: time; egfr testing; idylla egfr; treatment ... See more keywords